THE PRECISION ONCOLOGY CRO™
Move your medicine to market, faster.
As an oncology CRO (contract research organization) dedicated to precision medicine, Translational Drug Development (TD2) works with innovative biotech and pharma companies to bring rare cancer treatments to patients as quickly as possible.
As a TD2 client, you’ll have exclusive access to an integrated suite of tools to give your research the best chance of success and an expansive patient database that makes recruiting easier than ever.
OUR CAPABILITIES
Support for every research milestone.
Clinical Study Management
We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.
Preclinical
In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.
Regulatory Support
Your therapy’s journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.
PK/ADME
Drug metabolism and pharmacokinetic(DMPK) analyses are key to successful drug development and approval, and TD2 can help determine which tests are the best fit early through a diverse set of assays to support your program.
CUTTING-EDGE RESOURCES
Minimize risk during
drug development.
Protect your project against risk and give your new agents the greatest chance of success with our advanced scientific tools built around tumor models, combination strategies and mutational context identification. After all, the future of oncology therapeutic discovery depends on accurately defining the clinical research strategy that will give your treatment an advantage in the clinic and then aligning that strategy with execution.
REGULATORY FILINGS
An impact on modern-day oncology.
Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen. Less than two years later, we opened our doors on the campus of the Mayo Clinic in Scottsdale, Arizona. TD2 has helped more than 600 biotech and pharma companies in nearly two decades, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous clinical trials that have led to approvals in both rare and large indications.
HELPED
MORE THAN
850
biotech and
pharma companies
INVOLVED IN
MORE THAN
850
biotech and
pharma companies
TRANSITIONED
MORE THAN
850
biotech and
pharma companies
